Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Repotrectinib on the Pharmacokinetics of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants
Latest Information Update: 29 Jan 2026
At a glance
- Drugs Repotrectinib (Primary) ; Bupropion; Digoxin; Flurbiprofen; Metformin; Omeprazole; Rosuvastatin
- Indications Adenocarcinoma; CNS cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 26 Jan 2026 Status changed from not yet recruiting to recruiting.
- 06 Nov 2025 New trial record